Movetis Takes GI from J&J
This article was originally published in Start Up
Executive Summary
VCs love a part-baked start-up, and one of the best places to find them is within Big Pharma. So it was that Belgium-based Movetis NV raised a record €49 million ($63.4 million) A round in January with a bunch of gastrointestinal-focused assets from Johnson & Johnson.
You may also be interested in...
Institutionalizing Externalization At Big Pharma – The Third Leg
The pharmaceutical industry has a hard time saying goodbye to strategic assets. In fact, it’s much more adept at welcoming new ones: diversification – either geographic or into areas beyond pure-play pharmaceuticals – has become commonplace. But pharma needs to overcome its entrenched resistance to asset externalization, which should become a critical third leg in its attempts to build long-term shareholder value. Strategic, almost biotech-like externalization strategies should move from a peripheral to a core part of pharma’s activities. Why haven’t they already been embraced?
Venture Capital Firms Looking For Plan B
Companies are cheap, but money is expensive. Burn must be slowed, but without sacrificing value drivers. And finding the exit has never been more difficult. Can venture investors make the best of the worst of times
Venture Capital Firms Looking For Plan B
Companies are cheap, but money is expensive. Burn must be slowed, but without sacrificing value drivers. And finding the exit has never been more difficult. Can venture investors make the best of the worst of times